28 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Synthesis and SAR study of novel pseudo-steroids as potent and selective progesterone receptor antagonists.
Johnson and Johnson Pharmaceutical Research and Development
Parallel synthesis and SAR study of novel oxa-steroids as potent and selective progesterone receptor antagonists.
Johnson and Johnson Pharmaceutical Research and Development
Synthesis and identification of novel oxa-steroids as progesterone receptor antagonists.
Johnson and Johnson Pharmaceutical Research and Development
A bioisosteric approach to the discovery of indole carbinol androgen receptor ligands.
Johnson and Johnson Pharmaceutical Research and Development
Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-3beta inhibitors.
Johnson and Johnson Pharmaceutical Research and Development
Synthesis and evaluation of nonpeptide substituted spirobenzazepines as potent vasopressin antagonists.
Johnson and Johnson Pharmaceutical Research and Development
Design, synthesis, and biological evaluation of (2R,alphaS)-3,4-dihydro-2-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-5-[3-(trifluoromethoxy)-phenyl]-alpha-(trifluoromethyl)-1(2H)-quinolineethanol as potent and orally active cholesteryl ester transfer protein inhibitor.
Johnson and Johnson Pharmaceutical Research and Development
Potent 2'-aminoanilide inhibitors of cFMS as potential anti-inflammatory agents.
Johnson and Johnson Pharmaceutical Research and Development
4-Amino-6-piperazin-1-yl-pyrimidine-5-carbaldehyde oximes as potent FLT-3 inhibitors.
Johnson and Johnson Pharmaceutical Research and Development
Discovery of para-alkylthiophenoxyacetic acids as a novel series of potent and selective PPARdelta agonists.
Johnson and Johnson Pharmaceutical Research and Development
Dihydro-[1H]-quinolin-2-ones as retinoid X receptor (RXR) agonists for potential treatment of dyslipidemia.
Johnson and Johnson Pharmaceutical Research and Development
RXR-LXR heterodimer modulators for the potential treatment of dyslipidemia.
Johnson and Johnson Pharmaceutical Research and Development
Identification and optimization of anthranilic sulfonamides as novel, selective cholecystokinin-2 receptor antagonists.
Johnson and Johnson Pharmaceutical Research and Development
Inhibitors of unactivated p38 MAP kinase.
Johnson and Johnson Pharmaceutical Research and Development
The SAR of 4-substituted (6,6-bicyclic) piperidine cathepsin S inhibitors.
Johnson and Johnson Pharmaceutical Research and Development
Novel non-benzimidazole chk2 kinase inhibitors.
Johnson and Johnson Pharmaceutical Research and Development
4-Phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives, a novel class of selective delta-opioid agonists.
Johnson and Johnson Pharmaceutical Research and Development
Discovery and SAR studies of a novel series of noncovalent cathepsin S inhibitors.
Johnson and Johnson Pharmaceutical Research and Development
Parallel methods for the preparation and SAR exploration of N-ethyl-4-[(8-alkyl-8-aza-bicyclo[3.2.1]oct-3-ylidene)-aryl-methyl]-benzamides, powerful mu and delta opioid agonists.
Johnson and Johnson Pharmaceutical Research and Development
Synthesis and structure-activity relationships of 3,5-diarylisoxazoles and 3,5-diaryl-1,2,4-oxadiazoles, novel classes of small molecule interleukin-8 (IL-8) receptor antagonists.
Johnson and Johnson Pharmaceutical Research and Development
Synthesis and evaluation of spirobenzazepines as potent vasopressin receptor antagonists.
Johnson and Johnson Pharmaceutical Research and Development
N-alkyl-4-[(8-azabicyclo[3.2.1]-oct-3-ylidene)phenylmethyl]benzamides, micro and delta opioid agonists: a micro address.
Johnson and Johnson Pharmaceutical Research and Development
N,N-dialkyl-4-[(8-azabicyclo[3.2.1]-oct-3-ylidene)phenylmethyl]benzamides, potent, selective delta opioid agonists.
Johnson and Johnson Pharmaceutical Research and Development
Structure-activity relationships of N-acyl pyrroloquinolone PDE-5 inhibitors.
Johnson and Johnson Pharmaceutical Research and Development
Benzoxazinones as PPARgamma agonists. 2. SAR of the amide substituent and in vivo results in a type 2 diabetes model.
Johnson and Johnson Pharmaceutical Research and Development
Novel human histamine H(3) receptor antagonists.
Johnson and Johnson Pharmaceutical Research and Development
Bridged bicyclic vasopressin receptor antagonists with V(2)-selective or dual V(1a)/V(2) activity.
Johnson and Johnson Pharmaceutical Research and Development